<DOC>
	<DOCNO>NCT00216658</DOCNO>
	<brief_summary>The purpose study verify effectiveness , safety pharmacokinetics fentanyl transdermal matrix patch contain either 12.5 mcg/hr , 25 mcg/hr , 50 mcg/hr Japanese patient cancer pain switch minimum amount exist morphine preparation , equivalent less 45 mg/day oral morphine , oral oxycodone preparation equivalent less 30 mg/day .</brief_summary>
	<brief_title>Phase II Clinical Trial Fentanyl Transdermal Matrix Patch , Management Cancer Pain- Assessment Effectiveness , Safety Pharmacokinetics -</brief_title>
	<detailed_description>Fentanyl transdermal matrix patch narcotic analgesic agent . Compared exist reservoir-type Durotep® Patch , liable leakage drug solution contain alcohol , become cause skin irritation . Also new formulation become available small one 12.5 mcg/hr small Durotep® Patch 25 mcg/hr . This clinical trial plan ass effectiveness , safety pharmacokinetics fentanyl transdermal matrix patch initial transdermal dose 12.5 mcg Japanese cancer patient pain receive morphine preparation equivalent less 45 mg/day oral morphine ( le 30 mg suppository , less 15 mg injection ) , oral oxycodone preparation equivalent less 30 mg/day , fentanyl citrate injectable solution equivalent less 0.3 mg/day . After pre-treatment period one three day evaluate eligibility patient study , patient use 3 patch 10 day . Starting first day treatment 12.5 mcg/hr patch , fentanyl apply chest , upper arm appropriate site , replace new patch every three day ( ca . 72 hr ) . Total treatment duration ten day , dose adjustment allow .</detailed_description>
	<mesh_term>Pain , Intractable</mesh_term>
	<mesh_term>Fentanyl</mesh_term>
	<criteria>Patients cancer pain receive follow treatment constantly least 3days treatment period : ( 1 ) Morphine preparation equivalent le 45 mg/day oral morphine ( le 30 mg/day suppository , less 15 mg/day injectable preparation ) , ( 2 ) oral oxycodone preparation equivalent less 30 mg/day , ( 3 ) Fentanyl citrate injectable solution equivalent less 0.3 mg/day Patients pain intensity less equal 34 mm 100 mm Visual Analogue Scale ( VAS ) Patients establish diagnosis cancer type notify disease Patients may hospitalize application initial transdermal dose fentanyl transdermal matrix patch ( patient may ambulatory initial patch replace second dose ) Patients respiratory dysfunction chronic pulmonary disease Patients asthma Patients bradyarrhythmia Patients concurrent liver and/or kidney dysfunction accord late laboratory test value within 14 day start pretreatment observation period Patients organic brain disorder elevate intracranial pressure , disturbance consciousness/coma , brain tumor Patients psychoneurologic complication judge incapable self assessment Patients history drug dependency narcotic abuse Patients history hypersensitivity fentanyl opioid analgesic</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Fentanyl</keyword>
	<keyword>Cancer pain</keyword>
	<keyword>Japanese patient</keyword>
</DOC>